Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
Office: bldg. E35/186
Kamenice 753/5
625 00 Brno
Phone: | +420 532 23 5494 |
---|---|
E‑mail: |
social and academic networks: |
---|
Total number of publications: 73
2020
-
Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
Journal for ImmunoTherapy of Cancer, year: 2020, volume: 8, edition: 1, DOI
2019
-
CRISPR/Cas9 gene editing and functional screening in chronic lymphocytic leukemia
Year: 2019, type: Conference abstract
-
Epigenetic drug screen of a CD20-low expressing cell line revealed an unexpected role of Aurora kinase inhibitors in CD20 expression.
Year: 2019, type: Conference abstract
-
Epigenetic drug screen of CD20-low expressing cell line revealed possible treatment target.
Year: 2019, type: Conference abstract
-
Epigenetic drug screen on CD20 immunotherapy resistant cells revealed possible role of Aurora kinase inhibitors in CD20 expression regulation.
Year: 2019, type: Conference abstract
-
Performance of α-CD19 Chimeric Antigen Receptor T cells in genetically defined classes of Chronic Lymphocytic Leukemia
Year: 2019, type: Conference abstract
-
Revoluce v imunoterapii nádorů: CAR-T lymfocyty
Year: 2019, type: Conference abstract
-
The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia
Year: 2019, type: Conference abstract
2018
-
ASH 2017 – novinky laboratorní.
Year: 2018, type:
-
CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia
Year: 2018, type: Conference abstract